GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
SPORTRADAR WINS MAJOR BID FOR ATP RIGHTSLONDON and ST. GALLEN, Switzerland, March 13, 2023 (GLOBE NEWSWIRE) -- Sportradar, a subsidiary of Sportradar Group AG (Nasdaq: SRAD), has been selected as the successful bidder for the global ATP data and betting streaming rights starting 2024. It follows an extensive RFP process led by Tennis Data Innovations (TDI).
Sportradar is a world leading sports technology company, providing immersive experiences for sports fans and bettors worldwide. The company has been a supplier of official ATP Tour and Challenger Tour secondary data feeds since the start of 2022 and boasts a roster of partnerships spanning professional sports.
The RFP process was initiated by TDI in January 2023 and saw five bidders submit detailed proposals across multiple rounds, for a six-year rights cycle beginning in 2024. The process took to market rights that have grown significantly in value over more than a decade. The process followed the setup in 2020 of TDI as a specialist joint venture vehicle of ATP and ATP Media to oversee innovation, development, and commercial management of all data and betting streaming products for the ATP Tour and ATP Challenger Tour.
Sportradar’s commitment to product innovation for the downstream market and unrivalled development in advanced technologies such as computer vision and AI, in addition to its industry leading integrity services, were key considerations in the selection process.
David Lampitt, TDI CEO, said: "We are grateful to all the bidders who showed such commitment to our content throughout the selection process. Sportradar has been chosen as the best partner to deliver against our growth ambitions due to their combination of product capabilities, global reach and an innovative commercial model that preserved our ability to share in the continued growth of this market.
“Since the establishment of TDI, our mission has been clear – to create the most engaging data & streaming products and services for existing tennis fans and bring new fans to the game. If we get this right, we will deliver great returns for the sport. The competitive nature of this process, as well as the compelling successful bid from Sportradar, reflects the incredible value of ATP content. We look forward to forging a successful partnership together.”
Carsten Koerl, Sportradar CEO, said: “We are delighted that TDI has selected Sportradar as the successful bidder to support the enormous growth of the sport of tennis. The capabilities and global scale of our offerings will provide betting operators innovative, best-in-class products and tech savvy tennis fans a richer, more immersive experience that only Sportradar can deliver. Our expertise in developing advanced technologies, including computer vision and AI which create advanced analytics and data visualization, will drive new, compelling ways for fans to engage with tennis, while also safeguarding and upholding its integrity.”
SRAD---> $11.74 (+2.6%)
Last year:
How much is bet on March Madness? 2022 tournament could be biggest betting event in history
Provided by Dow Jones
Mar 21, 2022 4:21 PM UTC
By Weston Blasi
Since last year's tournament, more U.S. states have legalized mobile sports betting
The 2022 men's March Madness tournament will likely be the biggest sports betting event in U.S. history.
According to estimates from PlayUSA, $3 billion is expected to be legally wagered during this year's college basketball tournament, doubling totals from 2021.
___________________________
This year:
This is How Much Money is Expected to be Bet on 2023 March Madness
Written by:
Don Shapiro
Published on:
Mar/13/2023
“March Madness is one of the best traditions in American sports—and America’s most wagered-on competition. Critically, the expansion of regulated sports betting over the past five years has brought safeguards to more than half of American adults who can now bet legally in their home market.” - AGA President and CEO Bill Miller.
How much will be bet during the 2023 NCAA Men's Tournament?
A quarter of all American adults (68 million) plan to wager $15.5 billion on this year’s NCAA Men’s Division I Basketball Tournament, according to a new survey from the American Gaming Association (AGA).
Amazingly, three fourths of those surveyed say this will be their first time betting on March Madness online.
______________________________________
______________________________________
$3B to $15B in one year. On one tournament.Sports betting is exploding obviously.
FWIW... SRAD is not a betting website... they sell the picks and shovels to those websites. They wrote the book on in-app betting.
This stock is sooo underappreciated. Or undiscovered.
IPO'd in 9/21 at $28 ---- refused to be SPAC'd
Projected EPS growth for the next 5 years: 170%
QoQ revenue growth 30%+
They went cashflow positive last quarter.
No debt
$300M cash
$3B marketcap
FW PE 60
P/S (ttm) 4.6
EV/EBITDA ~14
No insider sales.
Swiss company
76% gross margin last Q
7% net margin
As a software company, that net margin should only improve.
#1 provider of B2B solutions to the sports betting industry worldwide.
Odds, risk management, traffic generation, play by play betting... the whole 9 yards.
Or so they say.
$11.76 close today.
Earnings tomorrow.
Last edited:
Why's the Market down?
Good morning. If it can be good.
It's never a positive event when I have an 8:30 meeting uptown.///
Lost of moving parts. Credit Suiss etc. The HF has some aggressive types who want to take advantage of the banking dislocation- they may do so -- Personally, I'd rather wait til the dust settles.
Gold is through the Fing* roof. My poor wife makes jewelry. Silver anyone-?
My best advice is think quality:
We have two major stocks that are basing and I feel are good buys
DIS & RH.
If you use yesterdays lows on each name, I think they will close above today.
Create positions in these names as the shoulders to build on for future portfolios.
I have a phone conf with Big Pete and crew and will touch base at 11:30>
It's never a positive event when I have an 8:30 meeting uptown.///
Lost of moving parts. Credit Suiss etc. The HF has some aggressive types who want to take advantage of the banking dislocation- they may do so -- Personally, I'd rather wait til the dust settles.
Gold is through the Fing* roof. My poor wife makes jewelry. Silver anyone-?
My best advice is think quality:
We have two major stocks that are basing and I feel are good buys
DIS & RH.
If you use yesterdays lows on each name, I think they will close above today.
Create positions in these names as the shoulders to build on for future portfolios.
I have a phone conf with Big Pete and crew and will touch base at 11:30>
Abbreviated))))))))))))))))))))))))))
--Smartsheet rises 13.5% 09:47 SMAR
--Liberty Formula One price target raised to $60 from $56 at Deutsche Bank 09:19 FWONA
--Bank OZK upgraded to Buy from Neutral at UBS 08:53 OZK
--Webster Financial initiated with a Buy at UBS 09:07 WBS
--Smartsheet rises 13.5% 09:47 SMAR
--Liberty Formula One price target raised to $60 from $56 at Deutsche Bank 09:19 FWONA
--Bank OZK upgraded to Buy from Neutral at UBS 08:53 OZK
--Webster Financial initiated with a Buy at UBS 09:07 WBS
This is kind of interesting-- Higher doses can bring greater results / and more side effefcts
it cuts both ways but often you get abetter read out.
Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome
Wed, March 15, 2023, 7:00 AM EDT
In this article:
STOK
-4.22%
– Dosing anticipated to start in the coming weeks –
– Company remains on track for its planned data readouts from the Phase 1/2a MONARCH and ADMIRAL studies in 2023 –
BEDFORD, Mass., March 15, 2023--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that the FDA will allow the administration of a higher single dose of STK-001 (70mg) in its ongoing Phase 1/2a MONARCH study of children and adolescents with Dravet syndrome. This new 70mg single dose cohort in MONARCH will complement the ongoing evaluation of multiple doses of 70mg in the ADMIRAL study.
Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures beginning within the first year of life. Complications of the disease often contribute to poor quality of life for patients and their caregivers. Despite available anti-seizure medicines, seizures are not adequately controlled for more than 90% of patients. STK-001 is a proprietary antisense oligonucleotide (ASO) being developed by Stoke as the first potential new medicine to address the genetic cause of Dravet syndrome.
"There is an urgent need for a disease modifying approach to treat Dravet syndrome, a devastating disease with effects that go beyond seizures and impact quality of life for patients and their families," said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics. "We thank the FDA for its timely review of the clinical data from our ongoing studies. We expect data from this new dose cohort to provide information about the potential effects and durability of a single dose of 70mg. We look forward to dosing the first patient in the coming weeks and to be able to include preliminary findings in our anticipated data readout in the second half of 2023."
Upcoming Anticipated Milestones
About Dravet Syndrome
Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures, beginning within the first year of life. Dravet syndrome is difficult to treat and has a poor long-term prognosis. Complications of the disease often contribute to a poor quality of life for patients and their caregivers. The effects of the disease go beyond seizures and often include intellectual disability, developmental delays, movement and balance issues, language and speech disturbances, growth defects, sleep abnormalities, disruptions of the autonomic nervous system and mood disorders. The disease is classified as a developmental and epileptic encephalopathy due to the developmental delays and cognitive impairment associated with the disease. Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP. There are no approved disease-modifying therapies for people living with Dravet syndrome. One out of 16,000 babies are born with Dravet syndrome, which is not concentrated in a particular geographic area or ethnic group.
About STK-001
STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials. Stoke believes that STK-001, a proprietary antisense oligonucleotide (ASO), has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both occurrence of seizures and significant non-seizure comorbidities. STK-001 has been granted orphan drug designation by the FDA and the EMA, and rare pediatric disease designation by the FDA as a potential new treatment for Dravet syndrome.
it cuts both ways but often you get abetter read out.
Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome
Wed, March 15, 2023, 7:00 AM EDT
In this article:
STOK
-4.22%
– Dosing anticipated to start in the coming weeks –
– Company remains on track for its planned data readouts from the Phase 1/2a MONARCH and ADMIRAL studies in 2023 –
BEDFORD, Mass., March 15, 2023--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that the FDA will allow the administration of a higher single dose of STK-001 (70mg) in its ongoing Phase 1/2a MONARCH study of children and adolescents with Dravet syndrome. This new 70mg single dose cohort in MONARCH will complement the ongoing evaluation of multiple doses of 70mg in the ADMIRAL study.
Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures beginning within the first year of life. Complications of the disease often contribute to poor quality of life for patients and their caregivers. Despite available anti-seizure medicines, seizures are not adequately controlled for more than 90% of patients. STK-001 is a proprietary antisense oligonucleotide (ASO) being developed by Stoke as the first potential new medicine to address the genetic cause of Dravet syndrome.
"There is an urgent need for a disease modifying approach to treat Dravet syndrome, a devastating disease with effects that go beyond seizures and impact quality of life for patients and their families," said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics. "We thank the FDA for its timely review of the clinical data from our ongoing studies. We expect data from this new dose cohort to provide information about the potential effects and durability of a single dose of 70mg. We look forward to dosing the first patient in the coming weeks and to be able to include preliminary findings in our anticipated data readout in the second half of 2023."
Upcoming Anticipated Milestones
- Data from patients treated with multiple 45mg doses of STK-001 are anticipated in mid-2023.
- Data from patients treated with 70mg of STK-001 in MONARCH (single dose) and ADMIRAL (multiple doses) are anticipated in the second half of 2023.
- The Company expects to complete the Phase 1/2a studies of STK-001 in 2023 in order to initiate a Phase 3 program in 2024.
About Dravet Syndrome
Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures, beginning within the first year of life. Dravet syndrome is difficult to treat and has a poor long-term prognosis. Complications of the disease often contribute to a poor quality of life for patients and their caregivers. The effects of the disease go beyond seizures and often include intellectual disability, developmental delays, movement and balance issues, language and speech disturbances, growth defects, sleep abnormalities, disruptions of the autonomic nervous system and mood disorders. The disease is classified as a developmental and epileptic encephalopathy due to the developmental delays and cognitive impairment associated with the disease. Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP. There are no approved disease-modifying therapies for people living with Dravet syndrome. One out of 16,000 babies are born with Dravet syndrome, which is not concentrated in a particular geographic area or ethnic group.
About STK-001
STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials. Stoke believes that STK-001, a proprietary antisense oligonucleotide (ASO), has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both occurrence of seizures and significant non-seizure comorbidities. STK-001 has been granted orphan drug designation by the FDA and the EMA, and rare pediatric disease designation by the FDA as a potential new treatment for Dravet syndrome.
Stoke Therapeutics, Inc. (STOK) Put on watch/
NasdaqGS - NasdaqGS Real Time Price.
9.37-0.46 (-4.68%)
As of 09:59AM EDT.
NasdaqGS - NasdaqGS Real Time Price.
9.37-0.46 (-4.68%)
As of 09:59AM EDT.
Gummy-Sportradar Group AG (SRAD)
(Go Small 150 shares)
NasdaqGS - NasdaqGS Real Time Price.
10.48-1.28 (-10.92%)<----- GO Time-!
As of 10:00AM EDT.
(Go Small 150 shares)
NasdaqGS - NasdaqGS Real Time Price.
10.48-1.28 (-10.92%)<----- GO Time-!
As of 10:00AM EDT.
Pattern
Bearish
Sportradar AG
Full Year 2022 revenue growth of 30% exceeds annual 2022 outlook
Fourth quarter ROW Betting segment revenue grew 29% with Adjusted EBITDA margin of 44%
Fourth quarter U.S. segment revenue grew 77%; positive Adjusted EBITDA for second consecutive quarter
2023 annual outlook with growth of 24% to 26% for revenue and 25% to 33% for Adjusted EBITDA
Bearish
Sportradar AG
Full Year 2022 revenue growth of 30% exceeds annual 2022 outlook
Fourth quarter ROW Betting segment revenue grew 29% with Adjusted EBITDA margin of 44%
Fourth quarter U.S. segment revenue grew 77%; positive Adjusted EBITDA for second consecutive quarter
2023 annual outlook with growth of 24% to 26% for revenue and 25% to 33% for Adjusted EBITDA